Active substances: Norfloxacin
Fourteen patients 15 percent failed to show a response to treatment. Of the 48 patients with UTI and defined complications, 36 75 percent had a cure, three 6 percent showed improvement, and therapy failed in nine 19 percent. The manufacturer only recommends use of norfloxacin during pregnancy when benefit outweighs risk.
Ciprofloxacin is being licensed for the treatment of Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli and Inhalational Anthrax post-exposure and levofloxacin was recently licensed for the treatment of Inhalational Anthrax post-exposure.
However, the Fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK.
Adverse effects In general, fluoroquinolones are well tolerated, with most side-effects being mild to moderate. The overall rate of adverse events in patients treated with fluoroquinolones is roughly similar to that seen in patients treated with other antibiotic classes.Medical uses The initial approval by the U. CHMP stated that doctors should not prescribe oral norfloxacin for complicated pyelonephritis.
Centers for Disease Control study found patients treated with fluoroquinolones experienced adverse events severe enough to lead to an emergency department visit more frequently than those treated with cephalosporins or macrolides, but less frequently than those treated with penicillins, clindamycin, sulfonamides, or vancomycin.
Among these, tendon problems and exacerbation of the symptoms of the neurological disorder myasthenia gravis are the subject of "black box" warnings in the United States.
Younger people typically experience good recovery, but permanent disability is possible, and is more likely in older patients.
Quisque rutrum. Aenean imperdiet.
Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.
Nam eget dui. Etiam rhoncus. Arch Intern Med. Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women.